1. Recent advances in the treatment of pancreatic cancer
- Author
-
Jordan Berlin, Dana Backlund Cardin, and Marc T. Roth
- Subjects
medicine.medical_specialty ,Pancreatic ductal adenocarcinoma ,Disease stages ,medicine.medical_treatment ,pancreatic cancer ,Context (language use) ,Review ,Systemic therapy ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Quality of life (healthcare) ,Pancreatic cancer ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,030212 general & internal medicine ,General Pharmacology, Toxicology and Pharmaceutics ,Intensive care medicine ,Solid tumor ,General Immunology and Microbiology ,business.industry ,Articles ,General Medicine ,Immunotherapy ,medicine.disease ,Neoadjuvant Therapy ,Pancreatic Neoplasms ,030220 oncology & carcinogenesis ,Quality of Life ,business ,Carcinoma, Pancreatic Ductal - Abstract
Pancreatic ductal adenocarcinoma is one of the deadliest solid tumor malignancies and is projected to become a leading cause of cancer-related death in coming years. Improving quality of life and survival amongst these patients will require new ideas and novel therapies in a multidisciplinary approach. This review will cover the most recent advances in the comprehensive treatment of pancreatic cancer and place them within a historical context when necessary. Treatment of all disease stages will be discussed, but the focus is on systemic therapy as novel drugs and new treatment combinations enter the clinic. This will include more aggressive chemotherapy in earlier disease stages, approved uses for immunotherapy, and targetable mutations. In addition, negative trials of importance and controversial topics will be noted.
- Published
- 2020
- Full Text
- View/download PDF